Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01220895
Other study ID # CM-2009-01
Secondary ID
Status Completed
Phase Phase 2
First received October 13, 2010
Last updated January 23, 2018
Start date October 2010
Est. completion date January 2014

Study information

Verified date January 2018
Source Cell Medica Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the potential clinical benefit of pre-emptive cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) for reducing recurrent CMV reactivation.


Description:

As with other herpes viruses, infection with CMV is thought to result primarily from reactivation of latent virus. Transmission of the virus can also occur from donor marrow infusion or from allogeneic red cell, leukocyte or platelet transfusions. However, in immunocompromised bone marrow transplant recipients, CMV is frequently reactivated and disease resulting from the progression of CMV infection is a major cause of infectious morbidity and mortality. CMV infection is a consequence both of the immunosuppression these patients receive and also may reflect delayed immune reconstitution in these patients following transplant. It is of particular concern to recipients of VUD (HLA-Volunteer Unrelated Donor) transplants who often receive lower doses of donor T cells in the transplant and who also require greater post-transplant immunosuppression for GVHD prophylaxis. CMV reactivation is most frequent in this group of transplant recipient.

One approach to improve reconstitution of immunity against viruses following allogeneic HSCT is to adoptively transfer donor-derived virus-specific T lymphocytes, which has been well documented with proven success. Existing evidence suggests that adoptive cellular therapy (ACT) can be an effective approach for treating viral reactivation following allo HSCT, with a minimal risk of inducing GVHD. The major advantage to the patient is likely to be avoidance of extended periods of therapy with antiviral medications that have significant associated morbidities, and sometimes require inpatient care. From a pharmacoeconomic viewpoint this would translate into a reduction of costs associated with standard antiviral therapies compared to the cost of adoptive cellular therapy.

It is anticipated that the use of very small numbers of highly specific T-cells will allow enough CMV-specific T-cells to be obtained in vitro from normal healthy CMV-seropositive donors from the peripheral blood transplant product after a single leucapheresis procedure and that the absence of concurrent lympholytic immunosuppression combined with a profoundly lymphopenic environment should allow for expansion and maintenance of the anti-CMV response in vivo.

This current study is a randomised prospective phase II study of pre-emptive adoptive cellular therapy for CMV following T cell depleted allogeneic HSCT from an unrelated donor. The study is based on earlier phase I-II studies of CMV-specific cellular therapy and our ongoing phase III study of CMV-specific adoptive cellular immunotherapy in immunocompromised recipients of allogeneic sibling donor HSCT based on selection of CMV-specific T cells by two different methodologies (CMV-IMPACT). The proof of safety in the sibling donor setting now strengthens the case for extending the therapy to the unrelated donor setting, where both potential risks and benefits are greater. The current study will investigate the use of CMV-specific T cells selected from mobilised blood collected at the time of stem cell apheresis by the multimer technology in the unrelated donor setting. The selection of CMV-specific T cells selected from a mobilised blood at the time of stem cell apheresis is in contrast to the methodology used in the CMV-IMPACT study where selection is performed on a non-mobilised blood product produced from a second study-dedicated apheresis. Two significant issues remain unresolved for the CMV-ACE/ASPECT study; are these infusions safe in the HLA-matched un-related donor setting and do CMV-reactive T cells derived from the transplant product have equivalent activity in vivo to cells derived from a second apheresis as used in the sibling donor study (CMV-IMPACT study). The study will test the hypothesis that ACT can augment the impaired CMV immune function post-transplant and reduce the requirement for CMV antiviral drug therapy without causing an increase in GVHD; and to determine the efficacy of pre-emptive CMV-specific adoptive cellular therapy following T cell depleted allogeneic HSCT with respect to reconstitution of CMV-reactive T cells. There are multiple methods for T cell depletion available, and differences between them will likely have an effect on immune reconstitution. The study will be restricted to patients receiving alemtuzumab-containing conditioning protocols, where the risk of CMV infection is greatest. ACT will be administered from day 21 post transplant for those receiving ex-vivo T-cell depleted grafts and day 28 for those receiving in vivo T cell depletion, as a single dose immediately upon a single CMV-DNA PCR+ result.

In summary the study is a multicentre, prospective, controlled, open label, randomised (2:1) study of pre-emptive infusion with CMV-specific T cells selected by the multimer selection technique plus standard CMV antiviral therapy versus standard CMV antiviral therapy alone.

The primary objective will be determine the efficacy of pre-emptive CMV-specific ACT following T cell depleted allogeneic HSCT with respect to reconstitution of CMV-reactive T cells and subsequent in vivo expansion of CMV-reactive T cells post infusion of ACT. In addition individual groups will be compared for duration of antiviral therapy and number of reactivation episodes, plus GVHD incidence.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date January 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria:

1. Age 16 years or older

2. cytomegalovirus seropositive allogeneic T cell depleted (alemtuzumab-containing conditioning regimen) hematopoietic stem cell transplant recipient with cytomegalovirus (CMV) seropositive unrelated donor

3. Patient Informed consent

1. Prepared to undergo additional study procedures as per study schedule

2. Patient has undergone counselling about risk

4. Donor engraftment (neutrophils > 0.5x109/l)(to be assessed prior to cytomegalovirus (CMV)-specific T cell infusion)

5. Single positive cytomegalovirus PCR result (And to be assessed prior to cytomegalovirus (CMV)-specific T cell infusion)

6. The donor will be selected from the Anthony Nolan Trust registry or other donor registries that have approved the protocol and consent procedure.

7. Donor must have met requirements of EU Tissue and Cells Directive(2004/23/EC) as amended and the UK statutory instruments pursuant therein.

8. Healthy, Cytomegalovirus (CMV)seropositive donor - having passed medical for stem cell donation

9. Subject and Donor must have negative serology for Human immunodeficiency virus (HIV), Hepatitis B and C, syphilis

10. human leukocyte antigen (HLA) type A*0101, A*0201, A*2402, B*0702 and B*0801

11. Donor informed consent for stem cell mobilisation leucapheresis and storage

Exclusion Criteria:

1. Pregnant or lactating women

2. Co-existing medical problems that would place the patient at significant risk of death due to Graft versus Host Disease (GVHD) or its sequelae

3. Human immunodeficiency virus infection

4. Active acute Graft versus Host Disease (GVHD) > Grade I (to be assessed prior to CMV-specific T cell infusion )

5. Concurrent use of systemic corticosteroids(to be assessed prior to cytomegalovirus (CMV)-specific T cell infusion )

6. Organ dysfunction (to be assessed prior to cytomegalovirus-specific T cell infusion ) as measured by:

1. creatinine > 200 uM/l

2. bilirubin > 50 uM/l

3. alanine transferase > 3x upper limit of normal

7. Donor pregnant or lactating

8. Donor platelets < 50x109/l

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CMV-specific T-cells, single infusion following single positive CMV PCR result
Intravenous ganciclovir 5mg/kg twice daily Oral valganciclovir 900mg twice daily Intravenous foscarnet 90 mg/kg twice daily

Locations

Country Name City State
United Kingdom QEH Birmingham Hospital Birmingham
United Kingdom Bristol Royal Hospital Bristol
United Kingdom Kings College Hospital London
United Kingdom Royal Free Hospital London
United Kingdom University College London Hospital London
United Kingdom Manchester Royal Infirmary Manchester
United Kingdom The Christie Manchester
United Kingdom Nottingham University Hospital - City Campus Nottingham
United Kingdom Churchill Hospital Oxford

Sponsors (4)

Lead Sponsor Collaborator
Cell Medica Ltd Leukaemia Lymphoma Research, National Health Service, Blood and Transplant, University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cytomegalovirus (CMV) specific immune reconstitution Primary endpoint will be the peak number of circulating Cytomegalovirus (CMV)-reactive T cells within the first two months, after single positive cytomegalovirus PCR result (or post adoptive cell therapy infusion) First two months
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Terminated NCT01037712 - In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Phase 4
Completed NCT00370006 - Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT01552369 - CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Phase 4
Completed NCT00223925 - Maribavir for Prevention of CMV After Stem Cell Transplants Phase 2
Active, not recruiting NCT05085366 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Phase 3
Completed NCT00942305 - Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients Phase 2
Completed NCT00373412 - Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge Phase 1
Completed NCT05105048 - A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 Phase 1
Completed NCT00386412 - TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant Phase 2
Completed NCT03382405 - Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults Phase 1
Completed NCT02454699 - Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers Phase 1
Active, not recruiting NCT03910478 - Dried Blood Spot Testing of CMV Detection in HCT Recipients N/A
Completed NCT01354301 - Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Phase 4
Active, not recruiting NCT01473849 - Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients N/A
Completed NCT00880789 - Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus Phase 1
Completed NCT00817908 - Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients N/A
Completed NCT00273143 - A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients. Phase 1
Completed NCT00194155 - Cytomegalovirus (CMV) Infection in Pregnancy N/A